ArgonautArgonautArgonautArgonaut
  • About Us
    • Business Model
    • Regulation
    • Community
    • Jason and the Argonauts
    • Disclaimer and Disclosure
  • Corporate Finance
  • Stockbroking & Research
    • Stockbroking
    • Research
    • Best Execution Policy
    • Administration Forms
    • Open an Account
  • Special Situations
  • News
    • Latest News
    • Morning Notes
    • Latest Research
  • Contact
    • Careers
      • Advisers
      • Graduate Program
      • Internship Program

Argonaut congratulates Botanix Pharmaceuticals on Placement

    Home News Argonaut congratulates Botanix Pharmaceuticals on Placement
    NextPrevious

    Argonaut congratulates Botanix Pharmaceuticals on Placement

    By admin | News | 0 comment | 22 May, 2017 | 0

    Argonaut has acted as Lead Manager to Botanix Pharmaceuticals Ltd (ASX: BOT) (“Botanix”) in its oversubscribed placement of A$7.4 million to new and existing institutional and sophisticated investors.

    The funds raised under the placement provides financial capacity for Botanix to execute on its strategy to advance the clinical development of Botanix’s dermatology products, BTX1503 and BTX1204, and to pursue the strategy of commercialising the Permetrex TM technology. The Phase 1A trial of BTX1503 is schedule to commence soon and the company expects to fast-track the clinical development of BTX 1204 which is a topical treatment for moderate to severe atopic dermatitis.

    Botanix’s Executive Director, Matthew Callahan said: “The overwhelming support for the Placement is a clear vote of confidence from the institutional and sophisticated investment community in relation to Botanix’s business strategy, speed of clinical development and unique focus on using synthetically derived cannabidiol and the PermetrexTM delivery technology in the novel treatment of dermatology conditions.

    Investor interest in our transaction reflects the confidence in the Botanix program and management’s plans to accelerate initial in-human trials and shorten the product development cycle. We thank all the investors who have supported Botanix.”

    Argonaut is delighted to provide ongoing support to Botanix and looks forward to working with the Company to continue to create further value for stakeholders.

    Additional information regarding Botanix can be found on the company’s website at www.botanixpharma.com.  
     

    No tags.

    NextPrevious
    • About Us
      • Business Model
      • Regulation
      • Community
      • Jason and the Argonauts
      • Disclaimer and Disclosure
    • Corporate Finance
    • Stockbroking & Research
      • Stockbroking
      • Research
      • Best Execution Policy
      • Administration Forms
      • Open an Account
    • Special Situations
    • News
      • Latest News
      • Morning Notes
      • Latest Research
    • Contact
      • Careers
        • Advisers
        • Graduate Program
        • Internship Program
    Argonaut

    Argonaut | The Natural Choice in Resources.
    © 2022 Argonaut.

    Corporate Finance
    Stockbroking & Research
    Contact Us

    Argonaut | Perth

    Level 30, Allendale Square, 77 St Georges Terrace Perth, WA, 6000 Australia

    clientservices@argonaut.com

    ABN 72 108 330 650

    Argonaut | Login

    Client Area Help
    Register for Access to Client Area
    Privacy Policy
    Financial Services Guide 
    Website Disclaimer

    Copyright 2022 | Website ⚡ by Start Digital